Bleiben Sie auf dem Laufenden

As outsourcing strategies evolve, drug developers are increasingly seeking manufacturing partners that can offer not only capacity, but also flexibility, speed, and risk mitigation. One of the most important enablers of this shift is the growing use of single-use systems (SUS) in sterile manufacturing.

In an era marked by growing regulatory complexity and accelerated development timelines, the analytical laboratory within a CDMO has emerged as a vital strategic partner - exceeding its conventional role as a testing service provider. Analytical and microbiological laboratories embedded within CDMOs today must deliver more than routine testing - they must serve as dynamic enablers of project success.

As lyophilization becomes increasingly important for modern biologics and complex formulations, the industry is paying closer attention to the factors that drive consistency, stability, and manufacturability. One of the most decisive of these factors — and one that is still widely misunderstood — is ice nucleation, the moment when a liquid first forms ice crystals during the freezing stage of freeze-drying.

The oncology pipeline is transforming. More than 100 ADCs are currently in clinical development. These therapies offer unprecedented specificity—but they also introduce manufacturing requirements that differ fundamentally from conventional biologics.

The challenge of inspecting injectable products has grown significantly in recent years. The future of sterile manufacturing will depend on systems capable of combining speed, precision, automation, and data intelligence into a unified quality strategy.